Please login to the form below

Not currently logged in
Email:
Password:

Astellas, Daiichi Sankyo and Takeda to study biomarkers

Collaboration aims to establish comprehensive database to accelerate drug development

Biomarker testing 

Japanese pharmaceutical firms Astellas, Daiichi Sankyo and Takeda have joined forces to create a comprehensive database of biomarkers from healthy adults.

Each company will collect and analyse biomarker data from healthy volunteers, pooling this for comparison with patients taking part in preclinical and clinical research.

The patient data will come from Astellas, Daiichi Sankyo and Takeda clinical studies that use protein and metabolite biomarkers that will be carried out at their respective research bases in Japan.

In a joint statement, the three companies said they intend to publicise the resulting analysis, commenting that “fundamental biomarker data from healthy adults … has not been sufficiently accumulated globally” to date.

They hope that the research collaboration will subsequently accelerate the development of innovative new medicines, particularly in Japan but also worldwide.

The collection of the data samples will be overseen by Dr Thomas Hankemeier in association with a local CRO at Leiden University in the Netherlands.

Biomarkers are naturally occurring characteristics formed from ordinary biological, pathological or physiological processes and which can be objectively measured to document pharmacological responses to therapeutic intervention.

Biomarker collaborations have become increasingly common in the industry, with AstraZeneca's new drug discovery genomics consortium also planning to publish its findings. 

Similarly in 2015 Genentech partnered with 23andMe to analyse genomic data for Parkinson's disease. 

Meanwhile, at a regulatory level, the EMA's recent draft Alzheimer's disease research guidelines looks at the need for biomarkers.

Article by
Rebecca Clifford

23rd May 2016

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics